Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pernelle Noize

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Targeted Oncology|December 6, 2013
Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohortAnnie Fourrier-Réglat, Denis Smith, Magali Rouyer, et al.
BMC Medicine|April 21, 2017
Antidepressant use and cognitive decline in community-dwelling elderly people - The Three-City CohortIsabelle Carrière, Joanna Norton, Amandine Farré, et al.
Pharmacoepidemiology and Drug Safety|February 26, 2009
Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) StudyPernelle Noize, Fabienne Bazin, Carole Dufouil, et al.
Leukemia & Lymphoma|September 24, 2015
Patterns and effectiveness of bortezomib use according to age in the VESUVE cohortAngela Grelaud, Annie Fourrier-Réglat, Olivier Fitoussi, et al.
Therapie|March 13, 2019
Monitoring of drug misuse or potential misuse in a nationwide healthcare insurance database: A cross-sectional study in FranceAnne Bénard-Laribière, Pernelle Noize, Pierre-Oliver Girodet, et al.
Journal of Geriatric Oncology|April 18, 2016
Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohortMagali Rouyer, Annie Fourrier-Réglat, Denis Smith, et al.
British Journal of Clinical Pharmacology|July 14, 2020
Effectiveness of first-line cetuximab in wild-type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohortMagali Rouyer, Eric François, Antonio Sa Cunha, et al.
Targeted Oncology|August 24, 2015
Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA CohortMagali Rouyer, Denis Smith, Christophe Laurent, et al.
Clinical Colorectal Cancer|January 12, 2019
Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort StudyAmandine Gouverneur, Juliette Coutureau, Jérémy Jové, et al.
Leukemia & Lymphoma|July 2, 2013
Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort studyAnnie Fourrier-Réglat, Pernelle Noize, Thierry Facon, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Targeted Oncology|December 6, 2013
Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohortAnnie Fourrier-Réglat, Denis Smith, Magali Rouyer, et al.
BMC Medicine|April 21, 2017
Antidepressant use and cognitive decline in community-dwelling elderly people - The Three-City CohortIsabelle Carrière, Joanna Norton, Amandine Farré, et al.
Pharmacoepidemiology and Drug Safety|February 26, 2009
Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) StudyPernelle Noize, Fabienne Bazin, Carole Dufouil, et al.
Leukemia & Lymphoma|September 24, 2015
Patterns and effectiveness of bortezomib use according to age in the VESUVE cohortAngela Grelaud, Annie Fourrier-Réglat, Olivier Fitoussi, et al.
Therapie|March 13, 2019
Monitoring of drug misuse or potential misuse in a nationwide healthcare insurance database: A cross-sectional study in FranceAnne Bénard-Laribière, Pernelle Noize, Pierre-Oliver Girodet, et al.
Journal of Geriatric Oncology|April 18, 2016
Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohortMagali Rouyer, Annie Fourrier-Réglat, Denis Smith, et al.
British Journal of Clinical Pharmacology|July 14, 2020
Effectiveness of first-line cetuximab in wild-type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohortMagali Rouyer, Eric François, Antonio Sa Cunha, et al.
Targeted Oncology|August 24, 2015
Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA CohortMagali Rouyer, Denis Smith, Christophe Laurent, et al.
Clinical Colorectal Cancer|January 12, 2019
Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort StudyAmandine Gouverneur, Juliette Coutureau, Jérémy Jové, et al.
Leukemia & Lymphoma|July 2, 2013
Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort studyAnnie Fourrier-Réglat, Pernelle Noize, Thierry Facon, et al.
Pageof 6